CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard of CareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (64)


Name (Synonyms) Correlation
drug2335 Standard screening strategy Wiki 0.20
drug737 Delayed diagnostics Anyplex TMII RV16 Detection Wiki 0.20
drug1811 Physical Exercises Wiki 0.20
drug369 Blood and derivatives. Wiki 0.20
drug2001 RESP301, a Nitric Oxide generating solution Wiki 0.20
drug2427 TERA Intervention Wiki 0.20
drug2120 Ruxolitinib plus simvastatin Wiki 0.20
drug1141 Hypothermia Wiki 0.20
drug552 Chat-based support Wiki 0.20
drug256 Awake Proning Wiki 0.20
drug1211 Inhaled nitric oxide gas Wiki 0.20
drug1899 Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 Wiki 0.20
drug650 Convalescent Plasma 1 Unit Wiki 0.20
drug98 AWARD advice Wiki 0.20
drug2718 Zinc Gluconate Wiki 0.20
drug1479 Messaging Wiki 0.20
drug2476 Tested for SARS-CoV-2 (regardless of the result) Wiki 0.20
drug583 Clinical diagnosis of COVID-19 by a health care professional Wiki 0.20
drug1030 HLCM051 Wiki 0.20
drug398 Brequinar Wiki 0.20
drug2161 SMS-based support Wiki 0.20
drug216 Ascorbic Acid and Zinc Gluconate Wiki 0.20
drug929 Favipiravir + Standard of Care Wiki 0.20
drug1881 Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 Wiki 0.20
drug1330 Lenzilumab Wiki 0.20
drug444 COSH Self-help smoking cessation booklet Wiki 0.20
drug1039 Health warning leaflet Wiki 0.20
drug1721 Oxytocin Wiki 0.20
drug1589 New screening strategy Wiki 0.20
drug198 Antioxidation Therapy Wiki 0.20
drug157 Ampion Wiki 0.20
drug1880 Positive feedback Wiki 0.20
drug2272 Six-month ARV dispensing Wiki 0.20
drug105 Abivertinib Wiki 0.20
drug1341 LifeSignals Biosensor 1AX* Wiki 0.20
drug2173 STI-1499 Wiki 0.20
drug744 Desidustat Wiki 0.20
drug2052 Referral card Wiki 0.20
drug1655 Nutrition support Wiki 0.20
drug2782 community health worker support Wiki 0.20
drug1602 Nitazoxanide and atazanavir/ritonavir Wiki 0.20
drug2774 care as usual Wiki 0.20
drug651 Convalescent Plasma 2 Units Wiki 0.20
drug1584 Neuromuscular Blocking Agents Wiki 0.20
drug1179 Imatinib Mesylate Wiki 0.20
drug490 COVSurf Drug Delivery System Wiki 0.20
drug481 COVID-19 related health warning leaflet Wiki 0.20
drug2028 Rapid diagnostics using Anyplex TMII RV16 Detection Wiki 0.20
drug99 AWARD plus COVID-specific advice Wiki 0.20
drug2808 ensoETM device Wiki 0.20
drug2422 TD-0903 Wiki 0.14
drug1998 REGN10933+REGN10987 combination therapy Wiki 0.14
drug2880 mRNA-1273 Wiki 0.14
drug1696 Opaganib Wiki 0.11
drug2069 Remestemcel-L Wiki 0.11
drug2067 Remdesivir Wiki 0.10
drug215 Ascorbic Acid Wiki 0.10
drug512 Camostat Mesilate Wiki 0.09
drug3018 survey Wiki 0.08
drug2662 Vitamin C Wiki 0.06
drug923 Favipiravir Wiki 0.05
drug1822 Placebo Wiki 0.04
drug647 Convalescent Plasma Wiki 0.04
drug1086 Hydroxychloroquine Wiki 0.02

Correlated MeSH Terms (24)


Name (Synonyms) Correlation
D005335 Fever of Unknown Origin NIH 0.20
D000856 Anorexia Nervosa NIH 0.20
D000855 Anorexia NIH 0.20
D002637 Chest Pain NIH 0.20
D007035 Hypothermia NIH 0.20
D018352 Coronavirus Infections NIH 0.13
D003428 Cross Infection NIH 0.11
D045169 Severe Acute Respiratory Syndrome NIH 0.11
D012327 RNA Virus Infections NIH 0.10
D015658 HIV Infections NIH 0.08
D055371 Acute Lung Injury NIH 0.08
D004417 Dyspnea NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.07
D000077062 Burnout, Psychological NIH 0.06
D012127 Respiratory Distress Syndrome, Newborn NIH 0.06
D003141 Communicable Diseases NIH 0.05
D014777 Virus Diseases NIH 0.05
D007239 Infection NIH 0.04
D013577 Syndrome NIH 0.04
D013315 Stress, Psychological NIH 0.04
D055370 Lung Injury NIH 0.04
D012141 Respiratory Tract Infections NIH 0.04
D011014 Pneumonia NIH 0.03
D016638 Critical Illness NIH 0.03

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0002039 Anorexia HPO 0.20
HP:0002045 Hypothermia HPO 0.20
HP:0100749 Chest pain HPO 0.20
HP:0002098 Respiratory distress HPO 0.07
HP:0011947 Respiratory tract infection HPO 0.04
HP:0002090 Pneumonia HPO 0.03

There are 26 clinical trials

Clinical Trials


1 Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: The TERA Study

Youth Living with HIV (YLWH) often face unique challenges achieving high and sustained rates of adherence to their antiretroviral therapy (ART). Poor adherence can lead to unsuppressed virus, more advanced HIV disease and poorer health outcomes, eventually exhausting treatment options. To date however, there are few demonstrated interventions for youth failing first line therapy. This study will evaluate a novel intervention that uses remote coaching through video enabled counseling sessions, a 'smart' pill bottle that notifies an adherence coach when youth fail to open/close the device around dose time, and problem solving outreach by the coach when and as needed. This intensive 'boot camp' strategy is implemented for 12 weeks followed by observation through 48 weeks.

NCT03292432 HIV Infections Behavioral: TERA Intervention Behavioral: Standard of Care
MeSH:HIV Infections

Primary Outcomes

Description: Participants with HIV-1 RNA < 50 copies/mL within the week 12 window (+/- 14 days) are classified as successes. Participants with HIV-1 RNA >= 50 copies/ml or with no HIV-1 RNA measurement within the week 12 window are classified as failures.

Measure: Proportion of participants with plasma Human Immunodeficiency Virus - Type I ribonucleic acid (HIV-1 RNA) levels less than (<) 50 copies/mL at week 12

Time: 12 weeks post enrollment

Description: Participants with HIV-1 RNA < 200 copies/mL within the week 12 window (+/- 14 days) are classified as successes. Participants with HIV-1 RNA >= 200 copies/ml or with no HIV-1 RNA measurement within the week 12 window are classified as failures.

Measure: Proportion of participants with HIV-1 RNA < 200 copies/mL at week 12

Time: 12 weeks post enrollment

Secondary Outcomes

Description: Participants with HIV-1 RNA < 50 copies/mL within each week window (+/- 28 days) are classified as successes. Participants with HIV-1 RNA >= 50 copies/ml or with no HIV-1 RNA measurement within the week window are classified as failures.

Measure: Proportion of participants with HIV-1 RNA < 50 copies/mL at weeks 24, 36 and 48

Time: 24, 36 and 48 weeks post enrollment

Description: Participants with HIV-1 RNA < 200 copies/mL within each week window (+/- 28 days) are classified as successes. Participants with HIV-1 RNA >= 200 copies/ml or with no HIV-1 RNA measurement within the week window are classified as failures.

Measure: Proportion of participants with HIV-1 RNA < 200 copies/mL at weeks 24, 36 and 48

Time: 24, 36 and 48 weeks post enrollment

Description: Participants are classified as successes if both the week 12 (+/- 14 days) and week 48 (+/- 28 days) HIV-1 RNA measurements are < 200 copies/ml and at least one of the week 24 (+/- 28 days) or week 36 (+/- 28 days) HIV-1 RNA measurements is < 200 copies/ml. Otherwise the participant is classified as a failure.

Measure: Proportion of participants with HIV-1 RNA < 200 copies/mL at 12 weeks and maintained through 48 weeks

Time: 24, 36 and 48 weeks post enrollment

Description: For each participant, the percentage of days in each 7-day period in which all doses were taken is calculated, and then averaged across the 12 week interval (or number of weeks with available data).

Measure: Percent of days with all doses taken per week from weeks 0-12, 12-24, 24-36 and 36-48

Time: Enrollment through 48 weeks

Description: For each participant, the percentage of days in each 7-day period in which all doses were taken within the defined acceptable windows (within 4 hours for once/day ART and within 2 hours for twice/day ART) is calculated, and then averaged across the 12 week interval (or number of weeks with available data).

Measure: Percent of days with all doses taken within defined acceptable windows (within 4 hours for once/day ART and within 2 hours for twice/day ART) per week from weeks 0-12, 12-24, 24-36 and 36-48

Time: Enrollment through 48 weeks

Description: For each participant, the incidence rate during each 12 week interval is calculated as the ratio of the number of gaps between doses of >7 consecutive days relative to the number of days with data reported, times 100. Consecutive gaps of more than 7 days increase the gap count by one, e.g. missing 20 days counts as 2 gaps.

Measure: Incidence rate (per 100 days) of gaps between dosing of at least 7 consecutive days between weeks 0-12, 12-24, 24-36 and 36-48

Time: Enrollment through 48 weeks

2 Pilot Randomized Clinical Trial of Therapeutic Hypothermia Plus Neuromuscular Blockade vs. Standard of Care in COVID-19 Patients With Moderate to Severe ARDS - the Cooling to Help Injured Lungs (CHILL) Pilot Study

Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of ~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication of TH, often requiring paralysis with neuromuscular blocking agents (NMBA) to control. Since the recently completed NHLBI PETAL ROSE trial showed that NMBA had no effect (good or bad) in patients with moderate to severe ARDS, the investigators sought to evaluate whether TH combined with NMBA is beneficial in patients with ARDS. The investigators are scheduled to begin enrolling in a Department of Defense-funded Phase IIb multicenter RCT of TH (core temperature 34-35°C) + NMBA for 48h vs. usual temperature management in patients with ARDS with time on ventilator as the primary outcome. Since COVID-19 is now the most common cause of ARDS, we are conducting a pilot study to examine the safety and feasibility of including patients with COVID-19-associated ARDS in our upcoming trial. In this pilot, we will randomize 20 patients with COVID-19 and ARDS to either TH+NMBA for 48h or usual temperature management. The primary outcome is achieving and maintaining the target temperature. Secondary outcomes include safety, physiologic measures, mortality, hospital and ICU length of stay, and serum biomarkers collected on days 0, 1, 2, 3, 4, and 7.

NCT03376854 Respiratory Distress Syndrome, Adult Sars-CoV2 Device: Hypothermia Drug: Neuromuscular Blocking Agents Device: Standard of Care
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Hypothermia
HPO:Hypothermia

Primary Outcomes

Description: The total time in hours from beginning of cooling to beginning of rewarming during which the patient's core temperature was within the target range of 34-35°C.

Measure: Targeted temperature compliance

Time: Randomization through day 3

Secondary Outcomes

Description: Adverse events expected during cooling, including hemorrhage, bradycardia, and hypotension.

Measure: Adverse event

Time: Randomization through study day 3

Description: Total number of days alive and not admitted to the ICU in the first 28 days after

Measure: 28-day ICU-free days

Time: Calculated at study day 28 or death (whichever occurs first)

Description: 28-day, 60-day, and 90-day mortality

Measure: Survival

Time: calculated at 28, 60, and 90 days

Description: SOFA score excluding neurologic component - based on PaO2/FiO2 (0-4), BP and pressor requirement (0-4), bilirubin level (0-4), platelet count (0-4), and creatinine (0-14) with total composite score 0-20

Measure: non neurologic Sequential Organ Failure (SOFA) scores

Time: At enrollment and study days 1, 2, 3, 4, 7, and 28

Description: Pulse ox reading

Measure: Oxygen saturation (SpO2)

Time: Measured at enrollment, every 4 hours on enrollment day, then once on day 2, 3, 4, 7 and 28

Description: On machine initiated breath

Measure: Plateau airway pressure

Time: Measured at enrollment, every 4 hours on enrollment day, then once on day 2, 3, 4, and 7 or until extubation whichever occurs first

Description: Direct ventilator measurement on machine initiated breath

Measure: Mean airway pressure

Time: Measured at enrollment, every 4 hours on enrollment day, then once on day 2, 3, 4, and 7 or until extubation whichever occurs first

Description: Plateau pressure - PEEP (machine initiated breath)

Measure: Airway driving pressure

Time: Measured at enrollment, every 4 hours on enrollment day, then once on day 2, 3, 4, and 7 or until extubation whichever occurs first

Description: Mean airway pressure x 100 x FiO2/SpO2

Measure: Oxygen saturation index

Time: Measured at enrollment, every 4 hours on enrollment day, then once on day 2, 3, 4, and 7 or until extubation whichever occurs first

Description: Measured continuously from iv catheter, urinary catheter, or esophageal probe.

Measure: Core temperature

Time: Measured continuously and recorded at enrollment, every 2 hours on the day of enrollment, and mornings on study day 2, 3, 4, and 7

Description: 24 hour urine volume

Measure: Urine output

Time: Daily on study day 1, 2, 3, 4, and 7

Description: performed in clinical lab

Measure: comprehensive metabolic panel

Time: Daily on study day 1, 2, 3, 4, and 7

Description: preformed in clinical lab

Measure: Complete blood count with differential count and platelet count

Time: Daily on study day 1, 2, 3, 4, and 7

Description: 10 ml blood draw

Measure: Biomarkers

Time: Daily on study day 1, 2, 3, 4, and 7

Description: performed in clinical lab

Measure: Serum electrolytes

Time: Every 8 hours until study hour 60

Description: Beside blood glucose testing

Measure: Blood glucose

Time: Every 4 hours until study hour 60

Description: Total number of days alive and not on a ventilator in the first 28 days after enrollment

Measure: 28-day ventilator-free days

Time: Calculated at study day 28 or death (whichever occurs first)

3 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.

NCT04292730 COVID-19 Drug: Remdesivir Drug: Standard of Care

Primary Outcomes

Description: The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol Remdesivir administration 7. Not hospitalized.

Measure: The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11

Time: Day 11

Secondary Outcomes

Measure: Proportion of Participants experiencing Treatment-Emergent Adverse Events

Time: First dose date up to 10 days plus 30 days

4 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.

NCT04292899 COVID-19 Drug: Remdesivir Drug: Standard of Care

Primary Outcomes

Description: The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol Remdesivir administration 7. Not hospitalized.

Measure: The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14

Time: Day 14

Secondary Outcomes

Measure: Proportion of Participants Experiencing any Treatment-Emergent Adverse Events

Time: First dose date up to 10 days plus 30 days

5 Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study

The purpose of this study is to examine the impact of ascorbic acid (vitamin c) and zinc gluconate in reducing duration of symptoms in patients diagnosed with coronavirus disease 2019 (COVID-19). Patients above the age of 18 who present to the Cleveland Clinic outpatient testing and receive a positive test for COVID-19 will be invited to participate.

NCT04342728 COVID Corona Virus Infection Dietary Supplement: Ascorbic Acid Dietary Supplement: Zinc Gluconate Dietary Supplement: Ascorbic Acid and Zinc Gluconate Other: Standard of Care
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Number of days to reach a 50 percent reduction in the cumulative 0-36 symptom score with each symptom evaluated on a 0-3 scale. Assessed symptoms are Fever, Cough, Shortness of Breath, Fatigue, Muscle or body aches, Headache, New loss of taste, New loss of smell, Congestion or runny nose, Nausea, Vomiting, Diarrhea. Each patient will have a composite score ranging from 0-36/day

Measure: Symptom Reduction

Time: 28 days

Secondary Outcomes

Description: The number of days required to reach a score of 0 from the symptom category of fever based on a 0-3 scale: 0 = ≤98.6, 1 = >98.6- 100.6, 2 = > 100.6 - 102.6, 3 = >102.6

Measure: Symptom Resolution: Fever

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of cough based on a 0-3 scale: 0 = no cough, 1 = mild, 2 = moderate, 3 = severe

Measure: Symptom Resolution: Cough

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of shortness of breath based on a 0-3 scale: 0 = no shortness of breath, 1 = with moderate intensity exercise 2 = with walking on flat surface 3 = short of breath with getting dressed or daily activities

Measure: Symptom Resolution: Shortness of Breath

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of fatigue based on a 0-3 scale: 1=mild fatigue, 2=moderate fatigue, 3=severe fatigue.

Measure: Symptom Resolution: Fatigue

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of muscle/body aches based on a 0-3 scale: 1=mild muscle/body aches, 2=moderate muscle/body aches , 3=severe muscle/body aches.

Measure: Symptom Resolution: Muscle/body aches

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of headache based on a 0-3 scale: 1=mild headache, 2=moderate headache, 3=severe headache.

Measure: Symptom Resolution: Headache

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of new loss of taste based on a 0-3 scale: 1=mild loss of taste, 2=moderate loss of taste, 3=severe loss of taste.

Measure: Symptom Resolution: New loss of taste

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of new loss of smell based on a 0-3 scale: 1=mild loss of smell, 2=moderate loss of smell, 3=severe loss of smell.

Measure: Symptom Resolution: New loss of smell

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of congestion/runny nose on a 0-3 scale: 1=mild congestion/runny nose , 2=moderate congestion/runny nose , 3=severe congestion/runny nose .

Measure: Symptom Resolution: Congestion/ runny nose

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of nausea on a 0-3 scale: 1=mild nausea, 2=moderate nausea, 3=severe nausea.

Measure: Symptom Resolution: Nausea

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of vomiting on a 0-3 scale: 1=mild vomiting, 2=moderate vomiting, 3=severe vomiting.

Measure: Symptom Resolution: Vomiting

Time: 28 days

Description: The number of days required to reach a score of 0 from the symptom category of diarrhea on a 0-3 scale: 1=mild diarrhea, 2=moderate diarrhea, 3=severe diarrhea.

Measure: Symptom Resolution: Diarrhea

Time: 28 days

Description: Total symptom composite score at day 5 of study supplementation: Symptom categories of fever based on a 0-3 scale: 0 = ≤98.6, 1 = >98.6- 100.6, 2 = > 100.6 - 102.6, 3 = >102; Cough on a 0-3 scale: 0 = no cough, 1 = mild, 2 = moderate, 3 = severe; Shortness of Breath on a 0-3: 0 = no shortness of breath, 1 = with moderate intensity exercise 2 = with walking on flat surface 3 = short of breath with getting dressed or daily activities; and Fatigue on a 0-3 scale: 0 = No fatigue/energetic, 1=mild fatigue, 2=moderate fatigue, 3=severe fatigue.

Measure: Day 5 Symptoms

Time: 5 days

Description: Differences in hospitalization events between the study arms

Measure: Hospitalizations

Time: 28 days

Description: Differences in severity of symptoms between study arms

Measure: Severity of Symptoms

Time: 28 days

Description: Differences in number of patients who were prescribed adjunctive medications for their diagnosis between study arms

Measure: Adjunctive Medications

Time: 28 days

Description: Differences in number of patients in study arms who experienced side effects from the supplements.

Measure: Supplementation Side Effects

Time: 28 days

6 Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients

A total of 278 patients are planned. All patients will be in an early-stage of COVID-19. They must be adults and hospitalized. In this study, all participating patients will receive the standard treatment provided according to the current treatment protocols for coronavirus disease. In addition to this treatment, each patient will be randomly assigned to receive additional treatment with convalescent plasma transfusion (CP; blood plasma from patients who have been cured of coronavirus), or continue with standard treatment but without adding transfusion. 50% of the chances of additional treatment with CP, and 50% of the chances of receiving only the standard treatment for coronavirus. The duration of the study shall be one month from the assignment of the treatment. The patient and the doctor will know the treatment assigned.

NCT04345523 COVID-19 Other: Blood and derivatives. Drug: Standard of Care

Primary Outcomes

Description: Proportion of patients in categories 5, 6 or 7 of the 7-point ordinal scale at day 15 Ordinal scale: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or ECMO. Death.

Measure: Category Changes in Ordinal Scale

Time: 15 days

Secondary Outcomes

Description: Time to change from baseline category to worsening into 5,6 or 7 categories of the ordinal scale

Measure: Time to category 5, 6 or 7 of the ordinal scale

Time: 29 days

Description: Mortality

Measure: Mortality of any cause at 15 days

Time: 15 days

Description: Mortality

Measure: Mortality of any cause at 29 days

Time: 29 days

Description: days free from oxygen supplementation

Measure: Oxygenation free days

Time: 29 days

Description: days free from mechanical ventilation

Measure: Ventilator free days

Time: 29 days

Description: Infusion-related adverse events Cumulative incidence of serious adverse events (SAEs) Cumulative incidence of Grade 3 and 4 adverse events (AEs).

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 29 days

Description: Quantitative total antibodies and neutralizing antibody activity against SARSCoV-2 in the sera from donors and patients using viral pseudotypes

Measure: Antibodies levels in CP donors recovered from COVID-19

Time: 3 months

Description: Change in PCR for SARS-CoV-2 in naso/oropharyngeal swabs and blood at baseline and on days 3, 5, 8, 11 (while hospitalized); and days 15 and 29 (if able to return to clinic or still hospitalized).

Measure: Viral load

Time: Days 1,3,5,8,11 and 29

Other Outcomes

Description: Serum levels of CRP, lymphocyte count, LDH, D Dimer,IL-6, coagulation tests at baseline and days 3, 5, 8, 11, 15 and 29.

Measure: Change in biological parameters

Time: Days 1,3,5,8,11 and 29

7 Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.

COVID-19's mechanism to enter the cell is initiated by its interaction with its cellular receptor, the angiotensin-converting enzyme. As a result of this union, a clathrin-mediated endocytosis process begins. This route is one of the therapeutic targets for which available drugs are being investigated in order to treat COVID-19 infection. This is one of the mechanisms blocked by drugs like ruxolitinib and chloroquine. Various drugs approved for clinical use that block the clathrin-mediated endocytosis pathway have been explored. It has been found that the best in vitro and in vivo results were obtained with statins, which also allowed generating a greater potent adaptive immune response. Therefore, statins and specifically simvastatin make it possible to block the entry process used by COVID-19, block inflammation by various mechanisms and increase the adaptive immune response. All of these processes are desirable in patients infected with COVID-19. Statins have been proposed to have beneficial effects in patients infected with MERS-COV, another coronavirus similar to COVID-19, but there have been no randomized studies supporting the use of statins in patients with COVID-19 infection. In this project we propose the combined use of one of these drugs, ruxolitinib with simvastatin, looking for a synergistic effect in the inhibition of viral entry and in the anti-inflammatory effect.

NCT04348695 Coronavirus Infection Drug: Ruxolitinib plus simvastatin Other: Standard of Care
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Insufficiency

Primary Outcomes

Description: Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 7 from randomization.

Measure: Percentage of patients who develop severe respiratory failure.

Time: 7 days

Secondary Outcomes

Description: Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 14 from randomization.

Measure: Percentage of patients who develop severe respiratory failure.

Time: 14 days

Description: Time from ICU admision to ICU discharge.

Measure: Length of ICU stay.

Time: 28 days

Description: Time from hospital admision to hospital discharge.

Measure: Length of hospital stay

Time: 28 days

Description: Percentage of patients alive at 6 months

Measure: Survival rate at 6 months

Time: 6 months

Description: Percentage of patients alive at 12 months

Measure: Survival rate at 12 months

Time: 12 months

Description: Percentage of patients who died from any cause 28 days after inclusion in the study

Measure: Survival rate at 28 days

Time: 28 days

Description: Percentage of patients with each AE by grade in relation with total number of treated patients

Measure: Percentage of patients with each AE by grade

Time: 28 days

Description: Percentage of patients who discontinued due to AEs in relation with total number of treated patients

Measure: Percentage of patients who discontinued due to AEs

Time: 28 days

8 A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia

The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and reduce the time to recovery in hospitalized subjects with severe or critical COVID-19 pneumonia.

NCT04351152 Coronavirus Disease 2019 (COVID-19) Pneumonia Biological: Lenzilumab Drug: Standard of Care
MeSH:Coronavirus Infections Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized, not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities).

Measure: Time to Recovery

Time: Up to 28 days

Secondary Outcomes

Measure: Incidence of Invasive Mechanical Ventilation and/or Death

Time: Up to 28 days

Measure: Incidence of severe acute respiratory distress syndrome (ARDS)

Time: Up to 28 days

Measure: Duration of Intensive Care Unit (ICU) Stay

Time: Up to 28 days

Measure: Ventilator-free Days

Time: Up to 60 days

Measure: Duration of Hospitalization

Time: Up to 28 days

Measure: Time to Improvement in 1 or 2 Categories using 8-point Ordinal Scale

Time: Up to Day 28

Measure: Time to Death

Time: Up to Day 28

Measure: Number of Subjects Alive and Off Oxygen

Time: Up to 60 days

Description: Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Measure: Percentage of Participants Experiencing Adverse Events

Time: Up to 60 days

Description: Using the NCI CTCAE version 5.0

Measure: Percentage of Participants Experiencing Serious Adverse Events

Time: Up to 60 days

Measure: Proportion of Subjects Discharged from Hospital

Time: Up to Day 60

Measure: All-cause Mortality and Proportion of Subjects Alive

Time: Day 28 and Day 60

Measure: Time to improvement in oxygenation for > 48 hours

Time: Up to Day 28

Measure: Incidence of Non-invasive Ventilation (or Use of High-flow Oxygen Device)

Time: Up to Day 28

Description: NEWS2 consists of: Physiological Parameters: respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), use of air or oxygen, systolic blood pressure (mmHg), pulse (per minute), consciousness and temperature (°C)

Measure: Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours

Time: Up to Day 28

Measure: Change from Baseline to Day 28 in Clinical status Based on the 8-point Ordinal Scale

Time: Up to Day 28

Measure: Duration of Time on Low-flow or High-flow Supplemental Oxygen

Time: Up to Day 28

9 Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19

To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.

NCT04358549 COVID-19 Drug: Favipiravir + Standard of Care Drug: Standard of Care

Primary Outcomes

Description: To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal sampling

Measure: Time to viral clearance

Time: Day 29

Secondary Outcomes

Description: To determine the clinical benefit of administering favipiravir plus SOC compared to SOC alone, clinical benefit will be measured using a study-specified ordinal scale on Day 15 in adult patients hospitalized with COVID-19.

Measure: Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15

Time: through Day 15

Description: The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, temperature.

Measure: Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)

Time: through Day 29

Description: Measurement of maximum plasma concentration

Measure: Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)

Time: through Day 14

Description: Measurement of minimum plasma concentration

Measure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin

Time: through Day 14

Description: Measurement of the area under the curve of plasma concentration versus time profile

Measure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC

Time: through Day 14

10 A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19

Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System

NCT04362059 Respiratory Infections Device: COVSurf Drug Delivery System Other: Standard of Care
MeSH:Respiratory Tract Infections
HPO:Respiratory tract infection

Primary Outcomes

Description: To assess the improvement in oxygenation as determined by the PaO2/FiO2 ratio after treatment with study treatment

Measure: Oxygenation Improvement

Time: 3 months

Description: To assess the improvement in pulmonary ventilation as determined by the Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO2]/1000 after study treatment.

Measure: Pulmonary ventilation Improvement

Time: 3 months

Secondary Outcomes

Description: To assess safety as judged by the frequency and severity of adverse events and severe adverse events (SAEs).

Measure: Safety Assessment of Frequency and Severity of Adverse Events

Time: 3 months

11 Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma

This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors. There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.

NCT04376034 COVID19 Coronavirus Infection Coronavirus Virus Diseases RNA Virus Infections Biological: Convalescent Plasma 1 Unit Biological: Convalescent Plasma 2 Units Other: Standard of Care
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Virus Diseases

Primary Outcomes

Description: Time it takes to identify eligible donors whom are willing to donate

Measure: Plasma Donor

Time: Measured in days for 365 days

Description: Time it takes the plasma collection center to contact willing donors whom are allowed to donate plasma

Measure: Plasma Donor

Time: Measured in days for 365 days

Description: Time from consent to infusion

Measure: Plasma Recipient

Time: Measured evey 24 hours up to 30 days

Description: Survival

Measure: Plasma Recipient

Time: Measured in days with 30 day from discharge follow-up

Secondary Outcomes

Description: Time until plasma is donated

Measure: Plasma Donor

Time: Measured every 24 hours up to 1 year

Description: Incident of treatment-Emergent Adverse Events [Safety and Tolerability]

Measure: Plasma Recipient

Time: Day 1, 2, 3, 4, 7, and 30 day

Description: Morbidity reduction

Measure: Plasma Recipient

Time: Day 1, 2, 3, 4, 7, and 30 day

Description: Reduced Length of Stay in hospital

Measure: Plasma Recipient

Time: Measured every 24 hours until patient discharged from hospital up to 1 year

Description: Reduced Length of Stay on Advance Respiratory Support

Measure: Plasma Recipient

Time: Measured every 24 hours until Off Advanced Respiratory Support up to 1 year

12 Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19

Introduction There are currently no treatments with demonstrated efficacy for COVID-19 infection. Epidemiological evidence points to the existence of intrinsic protection factors which make young persons and women more resistant to the infection, whereas older patients with multiple illnesses, above all with heart disease, are at greatest risk. This trial proposes treatment initiated in the early stages of the disease, when clinical worsening is most likely, with intravenous Oxytocin (OT), an endogenous hormone currently safely used in clinical practice. The selection of this molecule is based on numerous experimental and clinical observations, which show its activity in modulating resistance to pathogens, in mitigating overall cardiovascular risk, and in acting on the production of Nitric Oxide (ON) in the lungs, which is emerging as a key therapeutic factor for the improvement of respiratory function in patients with SARS-COVID 19. Finally, OT is physiologically produced by the human body, especially in the female sex and in the age ranges that coincide with most resistant patients. In routine clinical practice, OT exhibits an excellent therapeutic index, in absence of significant adverse effects. Primary aim To assess the effects of Oxytocin in addition to standard therapy, with respect to Standard of Care (SoC), in reducing the number of patients who enter a critical stage Secondary aim To describe: - Mortality 28 days after randomization - Time to mechanical ventilation during the study - Duration of dependency on oxygen supply - Length of stay - Temporal trend of clinical improvement (7-category ordinal scale) - Safety analysis

NCT04386447 Covid-19 Corona Virus Infection SARS-CoV 2 Drug: Oxytocin Drug: Standard of Care
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Virus Diseases

Primary Outcomes

Description: Proportion of cases who during 14 days exhibit one of the following conditions (the most severe): respiratory failure that requires mechanical ventilation organ failure that requires intensive care monitoring and treatment death

Measure: Proportion of cases who during 14 exhibit one of the following conditions

Time: 14 days

Secondary Outcomes

Description: Mortality 28 days after randomization

Measure: Mortality 28 days after randomization

Time: 28 days

13 Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia: A Pilot Study

A randomized controlled pilot study on the safety & efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.

NCT04422678 COVID-19 Drug: Imatinib Mesylate Drug: Standard of Care
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Proportion of patients with COVID-19 pneumonia progressed to critical illness in need for invasive mechanical ventilation.

Measure: Primary endpoint: Disease Progression

Time: 30 Days

Secondary Outcomes

Description: Improvement of Hypoxic index( PaO2 / FiO2) calculated daily

Measure: Improvement in Hypoxic Index

Time: From inclusion to 30 days follow up

Description: Hospital Length of stay

Measure: Hospital Length of Stay

Time: From inclusion to 30 days follow up

Description: Days on mechanical ventilation for patients needing intubation & invasive mechanical ventilation

Measure: Days on invasive mechanical ventilation

Time: From inclusion to 30 days follow up

Description: Difference in the median levels of serum IL-6, serum ferritin, CRP at the end of the follow up period between all groups

Measure: Inflammatory Markers

Time: From inclusion to 30 days

Description: Rate of viral clearance as monitored by SARS-COV-2 PCR

Measure: Viral clearance

Time: From inclusion to 30 days

Description: Difference in the overall evaluation of pulmonary infiltrative (improving / deteriorating) as assessed by imaging (Chest X-ray or Non-contrast pulmonary CT)

Measure: Radiological assessment

Time: From inclusion to 30 days

Description: Rate of serious adverse events (SAEs)

Measure: Safety of Imatinib

Time: From inclusion to 60 days

14 The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

NCT04425252 COVID-19 Drug: Brequinar Other: Standard of Care
MeSH:Coronavirus Infections

Primary Outcomes

Description: Adverse events are new onset medical conditions.

Measure: Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.

Time: Beginning at signing consent through Day 15.

Secondary Outcomes

Description: In-patient hospitalization, hospitalized in ICU-level care, or discharged

Measure: Hospitalization status

Time: Through Day 15

Description: Duration in days from admission to discharge

Measure: Duration of hospitalization

Time: Through Day 15

Description: National Early Warning Score (NEWS) 2. Composite score of respiration rate, oxygen saturation, systolic blood pressure, pulse, consciousness, and temperature.

Measure: NEWS2 Score

Time: Through Day 15

Description: Subject mortality status

Measure: Mortality

Time: Day 29

Description: Nasopharyngeal viral load by RT-PCR at days 1, 3, 5, 7, and 15

Measure: SARS-CoV-2 nasopharyngeal viral load

Time: Through Day 15

Description: Pro-inflammatory cytokines including TNFalpha, INFgamma, IL13, IL12p70, IL10, IL8, IL6, IL4 IL2, IL1-beta and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, serum ferritin, and fibrinogen

Measure: Inflammatory markers

Time: Through Day 15

Description: Plasma concentration of dihydroorotate

Measure: DHO Concentration

Time: Through Day 15

Description: Plasma concentration of brequinar

Measure: Brequinar Concentration

Time: Through Day 15

15 Use of Remote Patient Monitoring (RPM) Platform for COVID-19 Patient

The central hypothesis motivating this study is that remote patient monitoring (RPM) of infectious disease patients can efficiently facilitate self-isolation. Additionally, RPM can assist in more rapid identification of patients at risk, facilitate detection of patient deterioration, and enable early interventions, all of which play a vital role in resource utilization and outcomes.

NCT04425720 COVID Device: LifeSignals Biosensor 1AX* Other: Standard of Care

Primary Outcomes

Description: compare the number of in-patient admissions between the monitored and non-monitored patients

Measure: Monitored versus Non-Monitored in-patient admission

Time: 14 days

Description: compare the number of Emergency Department visits

Measure: Emergency Department Visits

Time: 14 days

Description: Length of stay of subject if hospitalized

Measure: Length of stay

Time: 14 days

Description: Survey given to patient to ask about satisfaction

Measure: patient satisfaction

Time: 14 days

Description: How often does a subject end up getting mechanical ventilation or ECMO

Measure: the incidence of mechanical ventilation and ECMO

Time: 14 days

Description: events requiring extended hospital stay

Measure: serious adverse events

Time: 14 days

16 Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial

Currently, no effective treatments are available for the COVID-19. Scientists and Researchers are working on many aspects of treatment options for the development of vaccination and medication to combat this life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains antibodies against COVID-19 which may be beneficial to severely sick COVID-19 patients. Investigator have recently concluded a pilot phase II open-label RCT on the efficacy of convalescent plasma in severe COVID 19 patients in which encouraging results were seen. Investigator plan to further study the efficacy and safety of convalescent plasma in COVID-19 severely sick patients through an RCT. Investigator will collect up to 500 ml Convalescent Plasma from the COVID-19 recovered persons after 14 days of clinical recovery with two consecutive SARS CoV-2 negative tests by PCR at least 24 hours apart. This plasma will be tested and frozen and stored. On requisition it will be thawed and sent to the treating center. Two doses of 250 ml convalescent plasma each will be transfused on two consecutive days to patients who fit the eligibility criteria (Severely sick COVID-19 patients) and are randomized to the convalescent plasma group along with the standard of care and the other group will receive standard of care alone. Data will be collected to study the benefits and adverse events related to convalescent plasma transfusion.

NCT04425915 COVID Biological: Convalescent Plasma Other: Standard of Care

Primary Outcomes

Description: The six-point scale is as follows: death=6; hospital admission for extracorporeal membrane oxygenation or mechanical ventilation=5; hospital admission for non-invasive ventilation or high-flow oxygen therapy=4; hospital admission for oxygen therapy (but not requiring high-flow or non-invasive ventilation)=3; hospital admission but not requiring oxygen therapy=2; discharged or having reached discharge criteria (defined as clinical recovery—ie, normalization of pyrexia, respiratory rate 94% on room air, and relief of cough, all maintained for at least 72 h)=1.

Measure: Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)

Time: Day 28

Secondary Outcomes

Measure: Proportion of patients in each category according to the ordinal scale

Time: 48 hours

Measure: Proportion of patients in each category according to the ordinal scale

Time: 7 day

Measure: Proportion of patients in each category according to the ordinal scale

Time: Day 14

Measure: Proportion of patients in each category according to the ordinal scale

Time: Day 28

Measure: Duration of oxygen therapy in both groups

Time: Day 28

Measure: Duration of hospital stay in both groups

Time: Day 28

Measure: Proportion of patients on mechanical ventilation at day 7 in both groups

Time: Day 7

Measure: Mortality in both groups

Time: Day 7

Measure: Mortality in both groups

Time: Day 28

Measure: Duration of Intensive Care Unit stay

Time: Day 28

Measure: Incidence of adverse effects in both groups

Time: Day 28

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 0

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 3

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 7

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 14

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 21

Description: IgG Titres against S1, RBD antigen, and SARS CoV2 neutralizing antibody titres

Measure: Presence of antibodies against SARS-CoV-2 in serum after plasma administration

Time: Day 28

Measure: Change in Cytokines in both groups

Time: Day 28

Description: Serum ferritin

Measure: Change in acute phase reactants in both groups

Time: Day 28

Measure: Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.

Time: Day 28

17 An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19

The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to study during the pivotal stage. The objective of the pivotal stage is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.

NCT04434248 COVID-19 Drug: Favipiravir Drug: Standard of Care

Primary Outcomes

Description: Percent of patients with undetectable SARS-CoV-2 RNA level on Day 10

Measure: Rate of viral elimination by Day 10 [pilot stage, dose selection]

Time: 10 Days

Description: Median time to reach undetectable SARS-CoV-2 RNA level

Measure: Time to viral elimination [pivotal stage]

Time: 28 Days

Description: Median time reach clinical improvement (2 points of the Ordinal Scale for Clinical Improvement) or discharge from the hospital

Measure: Time to clinical improvement [pivotal stage]

Time: 28 Days

Secondary Outcomes

Description: Percent of patients with undetectable SARS-CoV-2 RNA level

Measure: Rate of viral elimination

Time: Days 3, 5, 7, 9, and 11

Description: Median time [days] to reach normal levels of clinical indicators (body temperature, SpO2, breathing rate)

Measure: Time to normalization of clinical symptoms

Time: 28 Days

Description: Mean duration of oxygen therapy [days]

Measure: Duration of oxygen therapy

Time: 28 Days

Description: Change of lung damage level according to CT comparing to baseline [% of patients]

Measure: Change in the level of lung damage according to CT

Time: Days 15, 22, and 29

Description: Percent of patients transferred to the intensive care unit [% of patients]

Measure: Rate of transfer to the intensive care unit

Time: 28 days

Description: Percent of patients undergoing non-invasive lung ventilation [% of patients]

Measure: Rate of the use of non-invasive lung ventilation

Time: 28 days

Description: Percent of patients undergoing mechanical ventilation [% of patients]

Measure: Rate of the use of mechanical ventilation

Time: 28 days

Description: Percent of patients died within 28-days period [% of patients]

Measure: Mortality

Time: 28 days

Description: Determination of Cmax [ng/ml]

Measure: Peak plasma concentration (Cmax)

Time: Day 1

Description: Determination of Tmax [h]

Measure: Time to peak plasma concentration (Tmax)

Time: Day 1

Description: Determination of AUC0-t [ng*h/ml]

Measure: Area under the plasma concentration versus time curve (AUC0-t)

Time: 10 days

Description: Determination of Ctrough [ng/ml]

Measure: Trough plasma concentration (Ctrough)

Time: 10 days

18 Compassionate Use of Opaganib in Patients With Severe COVID-19

Shaare-Zedek Medical Center is a tertiary academic hospital in Jerusalem, Israel. On March 2020, a dramatic increase in the number of COVID-19 cases were diagnosed in Jerusalem. RedHill Biopharma, Ltd. offered opaganib under compassionate use for the treatment of COVID-19 patients. Eligible patients were those hospitalized with COVID-19 confirmed by a reverse-transcriptase-polymerase-chain-reaction assay. Patients received opaganib and Standard of Care. For the purpose of this study, the opaganib and Standard of Care patient group was compared to a group of patients that received only Standard of Care. Opaganib is an investigational drug under development and not approved for commercial distribution.

NCT04435106 Coronavirus Infections Drug: Opaganib Drug: Standard of Care
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: Measure the time to weaning from high-flow nasal cannula

Time: Every day from day 1 to day 14

Measure: Measure the time to breathing ambient (room) air

Time: Every day from day 1 to day 14

Secondary Outcomes

Measure: Measure change in lymphocyte count

Time: On day of admission or day 1 of treatment and every 2-4 days, till day 14

Measure: Measure change in C-reactive protein

Time: On day of admission or day 1 of treatment and every 2-4 days, till day 14

19 A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19

Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19

NCT04440007 Covid-19 Drug: Abivertinib Other: Standard of Care

Primary Outcomes

Description: Proportion of subjects alive and free of respiratory failure at Day 14

Measure: Proportion of subjects alive and free of respiratory failure at Day 14

Time: Randomization to Day 14

Secondary Outcomes

Description: Types, frequencies, and severities of adverse events and their relationships to STI-5656

Measure: Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)

Time: Randomization through study completion to 90 days

Description: Proportion of subjects alive and free of respiratory failure at Day 28

Measure: Proportion of subjects alive and free of respiratory failure at Day 28

Time: Randomization to Day 28

Description: Change in clinical status on a 0-8-point ordinal scale (lower score means better outcome; 0=uninfected, 8=dead)

Measure: Change in clinical status

Time: Randomization to Day 7, Day 14, and Day 28

Description: Proportion of subjects alive and discharged from ICU at Days 14 and 28

Measure: Discharge from ICU

Time: Randomization to Day 14 and Day 28

Description: Time from randomization to first occurrence of respiratory failure or death on study due to any cause up to Day 28

Measure: Time to respiratory failure or death

Time: Randomization to Day 28

20 A Randomized, Placebo-controlled Study to Evaluate Safety, Pharmacokinetics, Preliminary Efficacy of Three Dose Levels of a Single Dose of STI-1499 (COVI-GUARD), a COVID-19 Targeting Monoclonal Antibody, in COVID-19 Hospitalized Patients

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics, preliminary efficacy of four dose levels of a single dose of STI-1499 (COVI-GUARD), a COVID-19 targeting monoclonal antibody, in hospitalized patients with COVID-19

NCT04454398 Covid-19 Biological: STI-1499 Other: Standard of Care Drug: Placebo

Primary Outcomes

Description: Types, frequencies, and severities of adverse events and their relationships to STI-1499

Measure: Incidence of treatment-emergent adverse events (safety and tolerability of STI-1499)

Time: Randomization through study completion at 28 days

Secondary Outcomes

Description: All-cause mortality at Day 28

Measure: All-cause mortality

Time: Randomization through Day 28

Description: Change from baseline in clinical status on a 7-point ordinal scale where higher score means better outcome (1=Death, 7=Not hospitalized and no limitations on activities)

Measure: Change in clinical status

Time: Randomization to Day 7, 14, 28

Description: Change from baseline in SOFA score where lower score means better outcome

Measure: Change in Sequential Organ Failure Assessment (SOFA) score

Time: Randomization to Day 7, 14, 28

Description: Change from baseline in ratio of partial pressure of arterial oxygen to fraction of inspired oxygen

Measure: Change in PaO2:FiO2

Time: Randomization to Day 7, 14, 28

Description: Length of hospitalization of participants (followed up to Day 28)

Measure: Length of hospitalization

Time: Randomization up to Day 28

Description: Percentage of participants requiring mechanical ventilation at Day 7, 14, and 28

Measure: Percentage of participants requiring mechanical ventilation

Time: Randomization to Day 7, 14, 28

Description: Change from baseline in viral shedding as assessed by RT-PCR

Measure: Change in viral shedding

Time: Randomization to Day 7, 14, 21, 28

Description: Incidence of anti-drug antibody (ADA)

Measure: Immunogenicity of STI-1499

Time: Randomization to Day 21, 28

21 A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen Supplementation

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.

NCT04456452 COVID-19 Biological: Ampion Other: Standard of Care

Primary Outcomes

Description: Incidence and severity of adverse events

Measure: Incidence and severity of adverse events

Time: Primary endpoint at day 5

22 A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study

Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans. In this pilot study, 98 COVID-19 patients will be recruited into two group. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days. The time it takes for the germ that causes COVID-19 to be completely removed from the body (in nasal secretions) and the time to clinical improvement will be monitored in all patients and compared between the two groups.

NCT04459286 Covid-19 Drug: Nitazoxanide and atazanavir/ritonavir Other: Standard of Care

Primary Outcomes

Description: Proportion of patients with clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a 7-point ordinal scale, or both.

Measure: Time to clinical improvement

Time: 28 days

Description: Proportion of participants with SARS-CoV-2 polymerase chain reaction (PCR) negative result at Days 7, 10, 14 and 28

Measure: Time to SARS-CoV-2 negativity

Time: 28 days

Description: Temporal patterns of SARS-CoV-2 viral load quantified by RT-PCR from nasal swabs or sputum of patients receiving SOC alone versus SOC plus study drug

Measure: Difference in SARS-CoV-2 AUC

Time: 28 days

Secondary Outcomes

Description: Time to symptoms resolution as monitored by the Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) questionnaire with some modifications for COVID-19

Measure: Time to symptoms resolution

Time: 28 days

Measure: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14

Time: 14 days

Measure: Duration of hospitalization in survivors

Time: 28 days

Measure: Day 28 mortality

Time: 28 days

Measure: Time from treatment initiation to death

Time: 28 days

Measure: Proportion with viral RNA detection over time

Time: 28 days

23 NOCoV2 - An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 Requiring Supplemental Oxygen

The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.

NCT04460183 COVID-19 Drug: RESP301, a Nitric Oxide generating solution Other: Standard of Care

Primary Outcomes

Measure: Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14

Time: From Day 1 to Day 14

Secondary Outcomes

Measure: Change in room air oxygen saturation (SpO2) from baseline over time

Time: Baseline to Day 28

Measure: Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time

Time: Baseline to Day 28

Measure: Change from baseline on the modified WHO ordinal scale at each visit up to Day 28

Time: Baseline to Day 28

Measure: Time to improvement to a lower level (<4) of modified WHO ordinal scale

Time: Baseline to Day 28

Measure: Time to progression to a higher level (>4) of modified WHO ordinal scale

Time: Baseline to Day 28

Measure: Number of participants with adverse events and serious adverse events

Time: Baseline to Day 28

24 A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients

This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients. 100 mg of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.

NCT04463602 COVID-19 Drug: Desidustat Other: Standard of Care

Primary Outcomes

Description: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Death.

Measure: Change in Clinical status of subject on a 7-point ordinal scale

Time: Week 2

Secondary Outcomes

Description: PCR for SARS-CoV-2 in pharyngeal swab

Measure: PCR test

Time: Week 2 and Week 4

Description: Occurrence of supplemental Oxygen

Measure: Supplemental Oxygen

Time: Week 2 and Week 4

Description: Occurrence of Mechanical Ventilation

Measure: Mechanical Ventilation

Time: Week 2 and Week 4

Description: Occurence of Adverse events

Measure: Incidence of Treatment-Emergent Adverse Events

Time: Week 2 and Week 4

Description: Laboratory Assessments

Measure: Laboratory Assessments

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: C-reactive protein (CRP)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: Interleukin 6 (IL-6)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: D-dimer

Time: Week 2 and Week 4

25 A Study to Evaluate Antioxidant Therapy for Moderate to Severe COVID-19 With or Without Comorbidities

Finding effective strategies to treat or prevent the novel coronavirus disease that started in 2019 (COVID-19) is a global public health priority. Potential therapeutics and vaccines are now being investigated in over 1500 clinical trials. Clinical features of the disease include overproduction of reactive oxygen species which induces oxidative stress responses and contribute to acute lung injury. This presents a potential treatment strategy involving antioxidation therapy. In this pilot study, 90 COVID-19 patients aged 18-75 years will be recruited into two groups. The 45 patients in group 1 will receive the standard of care determined by their primary care providers while the 45 patients in group 2 will receive both the standard of care combined with daily antioxidant supplement for 14 days. All patients will be monitored for a total of 28 days with daily monitoring of symptoms and nasopharyngeal swab for SARS-CoV-2 test on days 3, 7, 14 and 28. The study will compare the following between the two groups: (1) the proportion of patients with clinical improvement (defined as live discharge from hospital, decrease of at least 2 points from baseline on a 7-point ordinal scale, or both), and (2) the proportion of patients with negative SARS-CoV-2 test by PCR on days 3, 7, and 14.

NCT04466657 Covid-19 Dietary Supplement: Antioxidation Therapy Other: Standard of Care

Primary Outcomes

Description: Time to clinical improvement (defined as time from randomization to either an improvement of two points on a 7-category ordinal scale or discharge from the hospital, whichever came first, or both)

Measure: Time to clinical improvement

Time: 28 days

Description: Proportion of participants with SARS-CoV-2 polymerase chain reaction (PCR) negative result at Day 14

Measure: Time to SARS-CoV-2 negativity

Time: 14 days

Secondary Outcomes

Description: Clinical status as assessed with the seven-category ordinal scale on day 14

Measure: Clinical status on day 14

Time: 14 days

Measure: Proportion of participants with SARS-CoV-2 PCR negative result at Day 7

Time: 7 days

Measure: Proportion of participants with SARS-CoV-2 PCR negative result at Day 28

Time: 28 days

Measure: 28 Day mortality

Time: 28 days

Measure: Duration of hospitalization in survivors

Time: 28 days

Measure: Time from treatment initiation to death

Time: 28 days

Other Outcomes

Measure: Adverse events during treatment

Time: 28 days

Description: Respiratory failure or Acute Respiratory Distress Syndrome, Acute Kidney Injury, secondary infection, shock, severe anemia, acute gastritis, unconsciousness, acute heart failure

Measure: Serious adverse events

Time: 28 days

Description: Nausea, vomiting, and diarrhea

Measure: Gastrointesntinal adverse events

Time: 28 days

Measure: Discontinuation of trial intervention before the end of protocol specified 14 days

Time: 14 days

26 RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor

To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

NCT04470544 Severe Acute Respiratory Syndrome Drug: Camostat Mesilate Other: Standard of Care
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

Primary Outcomes

Description: To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will change the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

Measure: Change in the proportion of patients alive and free from respiratory failure

Time: 28 Days

Secondary Outcomes

Description: To determine if reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with SOC treatment will change the proportion of patients alive and free of ventilator use or ECMO at Day 28 as compared to SOC treatment combined with placebo.

Measure: Change in the proportion of patients alive and free of ventilator use or ECMO

Time: 28 Days

Description: To determine if the combination of Camostat mesilate combined with SOC treatment will result in a changed mortality rate at 28 and 56 days as compared to SOC treatment combined with placebo.

Measure: Mortality Rate

Time: 28 and 56 Days

Description: Clinical change will be defined as a 2 or more point decease on the WHO ordinal scale. Time to clinical improvement will be calculated as the number of days from study entry until the earliest date of clinical change.

Measure: Clinical Change

Time: 14 and 28 Days

Description: Analyses for safety will include all participants who are randomized and received at least 1 dose of study treatment. Participants will be grouped according to the treatment to which they were randomized.

Measure: Adverse Events

Time: up to 56 days


Related HPO nodes (Using clinical trials)


HP:0011947: Respiratory tract infection
Genes 664
CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
Protein Mutations 1
H275Y
SNP 0